SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

DRTS

Alpha Tau Medical Ltd.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming data readouts in late 2026/early 2027 from ReSTART pivotal trial and REGAIN glioblastoma trial, which are key catalysts for FDA approval prospects. The Tolmar partnership provides non-dilutive funding and commercial pathway for prostate cancer.

DirectionNeutral
Confidencemedium
Horizonmonths

Alpha DaRT

▲ Bullish Named in this press release
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.27
T+0 close · Aug 10, 2026 · via day close
Latest settled
−1.68%
T+60 · $14.03
Vs SPY
−1.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $14.27entry
  2. T+1 · 3mo ago −2.80%α −3.05% · $13.87
  3. T+5 · 3mo ago −0.07%α +0.33% · $14.26
  4. T+20 · 2mo ago 0.00%α +1.06% · $14.27
  5. T+60 · 13d ago −1.68%α −1.20% · $14.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical reported Q2 2026 financial results with a net loss of $68.8 million for the six months ended June 30, 2026, compared to $18.8 million in the same period of 2025, driven by higher R&D expenses and a $41.4 million financial expense from warrant remeasurement. The company highlighted multiple clinical milestones including 100% local disease control in glioblastoma, completion of enrollment in its pivotal cSCC trial, and a strategic collaboration with Tolmar for prostate cancer. Cash balance of $104.8 million provides runway for ongoing trials.

Key Financial Metrics

EPS
−$0.76

Key Facts

  • Net loss for six months ended June 30, 2026 was $68.8 million ($0.76 per share) vs $18.8 million ($0.25 per share) in 2025
  • Cash and equivalents, short-term deposits and restricted deposits of $104.8 million as of June 30, 2026
  • Tolmar strategic collaboration includes $20M equity investment at 25% premium, $15M for manufacturing, and up to $161.5M in milestones
  • REGAIN glioblastoma trial showed 100% local disease control and 67% complete response rate in first three patients
  • ReSTART pivotal cSCC trial fully enrolled with 88 patients
  • Head and neck cancer combination study with pembrolizumab showed 100% objective response rate and 18.2-month median overall survival

Financial Impact

Net loss increased by $50M year-over-year; cash burn rate elevated; $20M equity investment from Tolmar at premium

net losscash positionR&D expensesfinancial expenses

Risk Factors

  • No revenue generating product; company is pre-commercial with significant operating losses
  • Warrant liability remeasurement creates volatility in reported financial results
  • Clinical trial results may not replicate in larger studies or lead to regulatory approval
  • Dependence on successful commercialization of Alpha DaRT technology

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342184

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026